我们能活到200岁？美媒：有戏——上海热线新闻频道 online.sh.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from online.sh.cn Daily Mail and Mail on Sunday newspapers.
Proactive weekly mining round-up: Rio Tinto, Bacanora Lithium, Caerus Mineral Resources.
A run-through of some of the week s mining stories
Jacques left the FTSE 100 mining giant after it blasted the 46,000-year-old Juukan Gorge heritage areas in Australia to access iron ore. On Thursday’s AGM, over 60% of shareholders voted against two resolutions on the firm’s remuneration report, but as it only an advisory measure the company decided to ignore the vote and carry on.
Bacanora Lithium PLC’s (LON:BCN) partner and major shareholder Ganfeng has made an offer to buy out the mining group. The Chinese giant says it will offer 67.5p per share, a 45% premium to the close yesterday and valuing AIM-listed Bacanora at £259mln, including shares to be issued through a recent placing. Ganfeng already has a 29% stake in Bacanora and also a 50% stake in Sonora, the junior miner’s lithium deposit in Mexico.
人类能活到200岁?美媒:有戏! news.hnr.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news.hnr.cn Daily Mail and Mail on Sunday newspapers.
Operator
Good afternoon and thank you for standing by. Welcome to the Meridian Bioscience Fiscal Second Quarter 2021 Earnings Conference Call. [Operator Instructions]
Now, I would like to hand the call over to Vice President of Investor Relations, Charlie Wood. Please go ahead.
Charles Wood
Vice President, Corporate Strategy, Business Development & Investor Relations
Thank you, Holly. Good morning and welcome to Meridian s fiscal 2021 second quarter earnings call. With me are Jack Kenny, Chief Executive Officer and Bryan Baldasare, Chief Financial Officer.
Please note that our SEC filings, earnings release and slides to accompany this call are available on our website at investor.meridianbioscience.com. We will post a copy of these prepared remarks after the call.
Message :
Required fields
CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021.
Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020):
Consolidated net revenues of $85.3 million, up 49% year-over-year
Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year
Diagnostics segment net revenues decreased 9% year-over-year to $31.9 million, up 5% from the first quarter of fiscal 2021
Signed agreement for 2nd grant from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx
SM) initiative - $5.5 million for ramping manufacturing of Revogene
® SARS-CoV-2 Assay
® Campy assay
Launched first Air-Dryable sample specific Master Mix for Blood